RNDr. Jitka Malčíková, Ph.D.
Assistant professor, Šárka Pospíšilová Research Group
Office: bldg. E35/258
Kamenice 753/5
625 00 Brno
Phone: | +420 532 23 4396 |
---|---|
E‑mail: |
social and academic networks: |
---|
Total number of publications: 288
2013
-
SF3B1 mutations frequently occur with both ATM mutations and TP53 mutations in CLL patients
Year: 2013, type: Conference abstract
-
The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy.
Leukemia & Lymphoma, year: 2013, volume: 54, edition: 9, DOI
-
The expression of a single microRNA -miR-34a - is a reliable marker for impairment of TP53-pathway in chronic lymphocytic leukemia
Year: 2013, type: Conference abstract
-
The expression of micrRNA-34a is a highly reliable for impairment of p53-pathway in CLL: development of clinically applicable assay
Year: 2013, type: Conference abstract
-
The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab
European Journal of Haematology, year: 2013, volume: 90, edition: 6, DOI
-
TP53 aberrations in chronic lymphocytic leukemia
Advances in Chronic Lymphocytic Leukemia, edition: Vyd. 1, year: 2013, number of pages: 23 s.
-
TP53 mutations associate with higher in vitro resistance of CLL cells to ofatumumab and rituximab
Year: 2013, type: Conference abstract
-
TP53 mutations but not ATM mutations associate with higher in vitro resistance of CLL cells to rituximab
Year: 2013, type: Conference abstract
-
Vyhledávání a sledování klonů s mutací TP53 v chronické fázi myeloproliferativních neoplazií (MPN)
Year: 2013, type: Conference abstract
-
Využití moderních genomických přístupů v diagnostice a léčbě lekémií
Year: 2013, type: